Aptinyx
Small Molecules for CNS Disorders

Aptinyx is a biopharmaceutical company developing novel modulators of the N-methyl-D-aspartate (NMDA) receptor for the treatment of neurological disorders such as neuropathic pain, traumatic brain injury, Parkinson’s Disease, and post-traumatic stress disorder (PTSD). The company is a spin-out of Naurex, a depression drug developer acquired by Allergan in 2015. The underlying work at both companies is based on research from the lab of Joseph Moskal, PhD at Northwestern University. NASDAQ: APTX


University
Northwestern University
Sector
Life Science
Status
Public
Initial Investment Stage
Early
View Website